Laying the foundations

India's embryonic structured products market is poised for takeoff, although it is currently governed by a set of restrictive regulations that prevent the use of over-the-counter derivatives and certain derivative instruments. Are the regulations anathema or just a necessary step towards a flourishing structured products market? Matt Cameron reports

The liberalisation of regulations concerning derivatives and structured products in India has proceeded at a moderate pace. Regulators have refused to bow to market pressure to relax their rules, and have instead implemented austere measures that they hope will protect investors and act as a tool to enhance market competition. Some market participants regard the process as overly protracted, while others accept that such caution is not always a bad thing.

The structured products market in India

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here